Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6112
-0.0104 (-1.67%)
May 13, 2026, 9:40 AM EDT - Market open
Vistagen Therapeutics Employees
Vistagen Therapeutics had 59 employees as of December 31, 2025. The number of employees increased by 11 or 22.92% compared to the same quarter last year.
Employees
59
Change
11
Growth
22.92%
Revenue / Employee
$13,373
Profits / Employee
-$1,136,373
Market Cap
24.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 59 | 11 | 22.92% | 59 | 0 |
| Sep 30, 2025 | 59 | 14 | 31.11% | 59 | 0 |
| Jun 30, 2025 | 57 | 16 | 39.02% | 57 | 0 |
| Mar 31, 2025 | 57 | 17 | 42.50% | 56 | 1 |
| Dec 31, 2024 | 48 | 11 | 29.73% | 48 | 0 |
| Sep 30, 2024 | 45 | 12 | 36.36% | 45 | 0 |
| Jun 30, 2024 | 41 | 9 | 28.13% | 41 | 0 |
| Mar 31, 2024 | 40 | 6 | 17.65% | 39 | 1 |
| Dec 31, 2023 | 37 | 5 | 15.63% | 37 | 0 |
| Sep 30, 2023 | 33 | -1 | -2.94% | 33 | 0 |
| Jun 30, 2023 | 32 | -6 | -15.79% | 32 | 0 |
| Mar 31, 2023 | 34 | -2 | -5.56% | 33 | 1 |
| Dec 31, 2022 | 32 | 1 | 3.23% | 32 | 0 |
| Sep 30, 2022 | 34 | 8 | 30.77% | 34 | 0 |
| Jun 30, 2022 | 38 | 14 | 58.33% | 38 | 0 |
| Mar 31, 2022 | 36 | 15 | 71.43% | 36 | 0 |
| Dec 31, 2021 | 31 | 20 | 181.82% | 31 | 0 |
| Sep 30, 2021 | 26 | 17 | 188.89% | 26 | 0 |
| Jun 30, 2021 | 24 | 15 | 166.67% | 24 | 0 |
| Mar 31, 2021 | 21 | 12 | 133.33% | 21 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Longeveron | 38 |
| Curis | 24 |
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| Outlook Therapeutics | 17 |
| Lantern Pharma | 16 |
| Serina Therapeutics | 13 |
VTGN News
- 1 day ago - Vistagen reports preliminary positive data on ongoing PALISADE-3 study - TheFly
- 1 day ago - Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 5 days ago - Vistagen announces completion of last patient visit in PALISADE-4 study - TheFly
- 5 days ago - Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Business Wire
- 20 days ago - AbCellera target is profile more attractive than Vistagen, says JonesResearch - TheFly
- 21 days ago - Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing - TheFly
- 21 days ago - Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - Business Wire
- 2 months ago - Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum - Transcripts